Polyregional aggregatometry of blood in patients with acute thrombosis as a potential model for preclicinal studies of new correctors of hemostasis system ex vivo

Abstract

Current recommendations to develop new pharmacological agents influencing hemostasis system are limited to the studies carried out on healthy volunteers in vitro, healthy lab animals and animals with model thrombosis in vivo. However, specific and seasonal peculiarities of hemostasis system in laboratory animals may not always adequately represent processes that occur during an event of cardiovascular accident. In this context, the main objective of this work is to study hemostasis system in patients with thrombotic events and to use the received data as a model for assessing the effectiveness of pharmacological agents as exemplified by aspirin and pentoxifylline in ex vivo. Experimental work is carried out on the blood of healthy male donors and patients with acute thrombosis. The findings show that completed thrombosis in one of the regions of coronary blood stream is not always accompanied by systemic tension of the coagulation system. The method of polyregional thromboelastography was used to study hemostasis system and to find out that hyperaggregation of platelets is a responsible part in the development of system hyperactivity of hemostasis in cases where it is registered. Pulmonary embolism, mesenteric ischemia and acute coronary syndrome is most often accompanied by systemic hyperaggegatioin of platelets, which can be used to assess the therapeutic efficacy of medicaments under conditions ex vivo. Aspirin and pentoxifylline are taken as examples to prove the necessity of preclinical studies for potential correctors of hemostatic system aimed to assess therapeutic effectiveness under conditions ex vivo in patients with completed thrombosis.

Correction of nutritional status in patients with focal liver diseases

“…Независимо от вида оперативного лечения помимо коррекции нутритивного статуса всем пациентам проводилась профилактика тромбоэмболических и инфекционных осложнений по показаниям [8,9], мониторинг центральной гемодинамики [11] и биохимических маркеров повреждения печени и нутритивной недостаточности [12].…”